6MJZ

Cryo-EM structure of Human Parainfluenza Virus Type 3 (hPIV3) in complex with antibody PIA174

6MJZ の概要

• エントリーDOI: 10.2210/pdb6mjz/pdb
• EMDBエントリー: 9135
• 分子名称: Fusion glycoprotein F0, PIA174 Fab Heavy chain, PIA174 Fab Light chain (3 entities in total)
• 機能のキーワード: hpiv3 envelope, asymmetric, complex, antibody, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Human parainfluenza virus 3; 詳細
• タンパク質・核酸の鎖数: 5
• 化学式量合計: 211110.57

構造登録者

Acharya, P.,Stewart-Jones, G.,Carragher, B.,Potter, C.S.,Kwong, P.D. (登録日: 2018-09-24, 公開日: 2018-11-14, 最終更新日: 2025-05-14)

主引用文献

Stewart-Jones, G.B.E.,Chuang, G.Y.,Xu, K.,Zhou, T.,Acharya, P.,Tsybovsky, Y.,Ou, L.,Zhang, B.,Fernandez-Rodriguez, B.,Gilardi, V.,Silacci-Fregni, C.,Beltramello, M.,Baxa, U.,Druz, A.,Kong, W.P.,Thomas, P.V.,Yang, Y.,Foulds, K.E.,Todd, J.P.,Wei, H.,Salazar, A.M.,Scorpio, D.G.,Carragher, B.,Potter, C.S.,Corti, D.,Mascola, J.R.,Lanzavecchia, A.,Kwong, P.D.
Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.
Proc. Natl. Acad. Sci. U.S.A., 115:12265-12270, 2018

PubMed Abstract: Parainfluenza virus types 1-4 (PIV1-4) are highly infectious human pathogens, of which PIV3 is most commonly responsible for severe respiratory illness in newborns, elderly, and immunocompromised individuals. To obtain a vaccine effective against all four PIV types, we engineered mutations in each of the four PIV fusion (F) glycoproteins to stabilize their metastable prefusion states, as such stabilization had previously enabled the elicitation of high-titer neutralizing antibodies against the related respiratory syncytial virus. A cryoelectron microscopy structure of an engineered PIV3 F prefusion-stabilized trimer, bound to the prefusion-specific antibody PIA174, revealed atomic-level details for how introduced mutations improved stability as well as how a single PIA174 antibody recognized the trimeric apex of prefusion PIV3 F. Nine combinations of six newly identified disulfides and two cavity-filling mutations stabilized the prefusion PIV3 F immunogens and induced 200- to 500-fold higher neutralizing titers in mice than were elicited by PIV3 F in the postfusion conformation. For PIV1, PIV2, and PIV4, we also obtained stabilized prefusion Fs, for which prefusion versus postfusion titers were 2- to 20-fold higher. Elicited murine responses were PIV type-specific, with little cross-neutralization of other PIVs. In nonhuman primates (NHPs), quadrivalent immunization with prefusion-stabilized Fs from PIV1-4 consistently induced potent neutralizing responses against all four PIVs. For PIV3, the average elicited NHP titer from the quadrivalent immunization was more than fivefold higher than any titer observed in a cohort of over 100 human adults, highlighting the ability of a prefusion-stabilized immunogen to elicit especially potent neutralization.

PubMed: 30420505
DOI: 10.1073/pnas.1811980115

実験手法

ELECTRON MICROSCOPY (4.3 Å)